Which of the following laboratory findings are true in systemic lupus erythematosus: a) leukocytosis, b) C-reactive protein is a better marker of disease activity than erythrocyte sedimentation rate, c) hemolytic anemia frequently occurs during the active phase, d) complement levels are high during the active phase, e) prolongation of activated partial thromboplastin time suggests coexistence of antiphospholipid syndrome?

Laboratory Findings in Systemic Lupus Erythematosus

Statement (e) is correct: prolongation of activated partial thromboplastin time (aPTT) in SLE strongly suggests coexistence of antiphospholipid syndrome, specifically lupus anticoagulant. 1, 2

Analysis of Each Statement

a) Leukocytosis is the rule in SLE - FALSE

Leukopenia, not leukocytosis, is characteristic of SLE. The disease typically causes cytopenias rather than elevated white blood cell counts. Leukocytosis is actually more commonly seen in Adult-Onset Still's Disease (AOSD), where 50% of patients have peripheral leukocyte counts >15×10⁹ cells/L 3. In SLE, leucopenia and lymphopenia are associated with disease activity and are part of the diagnostic criteria 4, 5.

• Key point: If you see leukocytosis in an SLE patient, think infection first, not disease activity
• Severe leucopenia has been associated with increased risk of infections 6

b) C-reactive protein is a better marker of disease activity than ESR - FALSE

ESR is superior to CRP for monitoring SLE disease activity. This is one of the unique features of SLE that distinguishes it from other inflammatory conditions.

The inflammatory response in SLE is atypical 7:

• CRP remains disproportionately low despite active disease, even when IL-6 levels are elevated
• The mechanism: IFN-α (elevated in SLE) causes IL-6 receptor shedding, creating soluble receptors that buffer IL-6 activity and prevent hepatic CRP production 8
• ESR correlates better with disease activity and levels up to 25-30 mm/h are proposed as upper normal limits in SLE 7

Clinical algorithm for interpreting inflammatory markers in SLE:

• CRP <10 mg/L with elevated ESR → likely lupus flare
• CRP 10-50 mg/L → consider severe flare with serositis or arthritis
• CRP >50-60 mg/L → strongly suspect bacterial infection 6, 7

c) Hemolytic anemia frequently occurs during the active phase - TRUE

Autoimmune hemolytic anemia (AIHA) is a recognized manifestation of active SLE, though less common than thrombocytopenia. Hemolytic anemia is part of the haematological manifestations that occur in approximately 39.6% of SLE patients 4.

• AIHA is associated with active disease and typically resolves when disease subsides 3
• Warm autoimmune hemolytic anemia occurs in approximately 10% of SLE cases 9
• C3 and/or C4 hypocomplementemia is simultaneously associated with hemolytic anemia 4

d) Complement levels are high during the active phase - FALSE

Complement levels (C3 and C4) are LOW during active SLE, not high. This is fundamental to understanding lupus pathophysiology.

• Hypocomplementemia indicates active disease, particularly renal involvement 10
• Low complement levels result from consumption during immune complex formation and activation of the complement cascade
• Testing for complement levels (C3 and C4) should be considered in patients with suspected lupus nephritis 10
• C3 and C4 hypocomplementemia is associated with multiple haematological manifestations including hemolytic anemia, leucopenia, and lymphopenia 4

e) Prolongation of aPTT suggests antiphospholipid syndrome - TRUE

A prolonged aPTT in SLE is NOT a contraindication to anticoagulation but rather indicates lupus anticoagulant/antiphospholipid syndrome. 1, 2

Critical clinical points:

• Antiphospholipid antibodies prolong aPTT by interfering with phospholipid-dependent coagulation tests in vitro
• Paradoxically, these patients are at INCREASED risk of thrombosis, not bleeding 1
• Patients fulfilling diagnostic criteria for antiphospholipid syndrome who experience thrombotic events should be considered for indefinite anticoagulation 1
• All patients with SLE, especially those with suspected kidney involvement, should be tested for antiphospholipid antibodies 10

Important caveat: While prolonged aPTT usually indicates lupus anticoagulant in SLE, rare cases of acquired factor VIII inhibitors (acquired hemophilia) can occur and cause life-threatening bleeding 11. The distinction is made through mixing studies and specific factor assays.

Testing algorithm for prolonged aPTT in SLE:

• Perform both dRVVT and aPTT-based lupus anticoagulant testing 2
• Conduct mixing studies and confirmatory tests with phospholipid addition
• Test for anticardiolipin and anti-β2 glycoprotein I antibodies
• If bleeding occurs despite prolonged aPTT, urgently evaluate for factor inhibitors 11

Summary Answer

The correct statements are (c) and (e). Hemolytic anemia occurs during active SLE phases, and prolonged aPTT suggests antiphospholipid syndrome. The other statements are false: SLE typically causes leukopenia (not leukocytosis), ESR is better than CRP for monitoring disease activity, and complement levels are LOW (not high) during active disease.